UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 205

Sortiert nach

Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis

Scientific reports, 2021-11, Vol.11 (1), p.22160-22160, Article 22160

2021

Volltextzugriff (PDF)

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms

Scientific reports, 2021-09, Vol.11 (1), p.17819-17819, Article 17819

2021

Volltextzugriff (PDF)

Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin

Therapeutic advances in hematology, 2021-12, Vol.12, p.20406207211063783-20406207211063783

2021

Volltextzugriff (PDF)

Practical issues in CAR T-cell therapy

Blood Research, 2023, 58(0), , pp.11-12

Byun, Ja Min

2023

Volltextzugriff (PDF)

Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?

Therapeutic advances in hematology, 2021, Vol.12, p.20406207211001135-20406207211001135

2021

Volltextzugriff (PDF)

Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation

Scientific reports, 2024-06, Vol.14 (1), p.13885-9, Article 13885

2024

Volltextzugriff (PDF)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)

Therapeutic advances in hematology, 2020, Vol.11, p.2040620720921046-2040620720921046

2020

Volltextzugriff (PDF)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM

PloS one, 2022-01, Vol.17 (1), p.e0260113-e0260113

2022

Volltextzugriff (PDF)

Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy

British journal of haematology, 2021-04, Vol.193 (1), p.101-112

2021

Volltextzugriff (PDF)

Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia

Scientific reports, 2020-06, Vol.10 (1), p.9370-9370, Article 9370

2020

Volltextzugriff (PDF)

Serum Erythropoietin level in anemia of elderly with unclear etiology

Scientific reports, 2023-09, Vol.13 (1), p.15902-15902, Article 15902

2023

Volltextzugriff (PDF)

ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application

BMC bioinformatics, 2023-02, Vol.24 (1), p.62-62, Article 62

2023

Volltextzugriff (PDF)

Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study

PloS one, 2022-01, Vol.17 (1), p.e0261671

2022

Volltextzugriff (PDF)

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Nature communications, 2024-03, Vol.15 (1), p.2776-2776, Article 2776

2024

Volltextzugriff (PDF)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.1-150, Article 150

2022

Volltextzugriff (PDF)

Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment

Genome medicine, 2022-09, Vol.14 (1), p.1-111, Article 111

2022

Volltextzugriff (PDF)

Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma

JCI insight, 2023-01, Vol.8 (2)

2023

Volltextzugriff (PDF)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm

Blood Research, 2023, 58(3), , pp.155-157

2023

Volltextzugriff (PDF)

Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement

Blood Research, 2023, 58(4), , pp.242-245

2023

Volltextzugriff (PDF)

A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation

BMC oral health, 2023-12, Vol.23 (1), p.1008-1008, Article 1008

2023

Volltextzugriff (PDF)

Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation

Clinical epigenetics, 2023-05, Vol.15 (1), p.75-75, Article 75

2023

Volltextzugriff (PDF)

Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients

Journal of Korean Medical Science, 2022, 37(6), , pp.1-5

2022

Volltextzugriff (PDF)

Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy

Cancer medicine (Malden, MA), 2024-04, Vol.13 (7), p.e7182-n/a

2024

Volltextzugriff (PDF)

PB2130: MAGNETISMM‐6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e039274c-n/a

2023

Volltextzugriff (PDF)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS

HemaSphere, 2023-08, Vol.7 (S3), p.e36320c6-n/a

2023

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(196)

Publikationsform

Sprache

Englisch
(184)
Koreanisch
(21)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms

Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin

Practical issues in CAR T-cell therapy

Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?

Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM

Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy

Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia

Serum Erythropoietin level in anemia of elderly with unclear etiology

ITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application

Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment

Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm

Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement

A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation

Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation

Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients

Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy

PB2130: MAGNETISMM‐6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS

Suchergebnisse filtern